General
Preferred name
Lubiprostone
Synonyms
Lubiprostone (hemiketal) ()
RU-0211 (hemiketal) ()
SPI-0211 (hemiketal) ()
Lubiprostona ()
SPI-0211 ()
Amitiza ()
Lubiprostone hemiketal ()
RU-0211 ()
P&D ID
PD016287
CAS
136790-76-6
333963-40-9
Tags
available
drug
Approved by
FDA
First approval
2006
Drug indication
Irritable bowel syndrome
Chronic idiopathic constipation
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Chemically lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 (). It acts as selective activator of ClC-2 chloride channels located at the apical aspect of gastrointestinal epithelial cells. (GtoPdb)
DESCRIPTION Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. It is used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. (Enamine Bioactive Compounds)
Compound Sets
23
AdooQ Bioactive Compound Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
External IDs
77
Properties
(calculated by RDKit )
Molecular Weight
390.22
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
11
Ring Count
2
Aromatic Ring Count
0
cLogP
4.31
TPSA
83.83
Fraction CSP3
0.9
Chiral centers
4.0
Largest ring
6.0
QED
0.51
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Chloride channel protein 2
Chloride channel
MOA
voltage-gated chloride channel activator
ClC-2 Channel Activators
Member status
member
Therapeutic Class
Anticonstipation Agents
Pathway
Membrane Transporter/Ion Channel
Source data